EPRX — EUPRAXIA PHARMACEUTICALS INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1581178 · British Columbia, Canada
Last close
$6.62
Market Cap
$437.41M
52W High
$9.32
52W Low
$5.63
ADV30
663,207
Next earnings
2026-11-10

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -16,164,032 -15,241,731 134,563,114 75,176,617 13,517,770
Jun 2026 0 — -18,103,173 -14,486,955 139,907,536 52,426,167 10,233,774
Mar 2026 0 — -15,957,045 -12,653,431 145,353,342 58,500,024 9,165,681
Dec 2025 0 — -16,162,620 -16,711,252 86,150,008 80,563,482 5,703,915

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-37,473,789
Investing CF
$-80,478,287
Financing CF
$151,448,193
CapEx
$-753,723
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.91
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-196,720,360
Inventory
—
Receivables
$688,219
ST Investments
$81,234,688
EBIT TTM
$-57,140,196
Pretax Income TTM
$-50,183,971
Interest Exp TTM
$0
Analysts
9

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -38,434,039 -38,576,143 86,150,008 5,703,915 82,041,436 -28,552,218
Dec 2024 0 -27,003,411 -25,502,536 34,942,355 3,103,386 33,404,803 -29,994,491
Dec 2023 0 -27,847,229 -28,220,796 20,266,229 19,373,903 2,216,207 -20,748,619
Dec 2022 0 -17,617,452 -18,489,629 19,122,249 11,914,395 7,786,525 -14,395,201

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.04

Peers — same industry

TickerNameMarket CapLastDaily %
INDP Indaptus Therapeutics, Inc. $442.36M $3.32 —
EOLS Evolus, Inc. $442.80M $6.69 —
ARVN ARVINAS, INC. $446.61M $6.82 —
PHAT Phathom Pharmaceuticals, Inc. $447.10M $5.50 —
PRTA PROTHENA CORP PUBLIC LTD CO $424.15M $8.26 —

News headlines (Yahoo Finance, 1h cache)

Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program
2026-11-10 21:16 · Yahoo
Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results
2026-11-10 21:01 · Yahoo
Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
2026-10-22 12:30 · Yahoo
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
2026-10-15 12:00 · Yahoo
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
2026-10-09 12:00 · Yahoo
Eupraxia Says Resolve Trial Updated Data Suggest Annual Dosing Possible in EoE Patients
2026-09-30 16:27 · Yahoo
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
2026-09-30 12:00 · Yahoo
Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice
2026-09-12 07:56 · Yahoo
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
2026-09-08 12:00 · Yahoo
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
2026-08-13 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.